06826 HAOHAI BIOTEC
- 25.600
- 0.0000.00%
HAOHAI BIOTEC News
HAOHAI BIOTEC (06826.HK) repurchased 0.039 million shares on January 2, spending 1.005 million Hong Kong dollars.
Gelonghui, January 2nd | HAOHAI BIOTEC (06826.HK) announced that on January 2, 2025, it spent 1.005 million Hong Kong dollars to repurchase 0.039 million shares at a price of 25.4-26 Hong Kong dollars per share.
Shanghai Haohai Biological Technology (688366.SH): Cumulatively repurchased 0.21% of shares.
On January 2, Gelonghui reported that Shanghai Haohai Biological Technology (688366.SH) announced that by December 2024, the company had cumulatively repurchased 354,596 A-shares through centralized price bidding, accounting for 0.15% of the company's total share capital of 233,193,695 shares, with a maximum Fill Price of 63.20 yuan/share, a minimum Fill Price of 60.58 yuan/share, and a total purchase amount of 21,850,342.17 yuan (excluding stamp duty, transaction commission, and other trading costs). As of December 31, 2024, the company had cumulatively repurchased A-shares through centralized price bidding.
Statistics on the abnormal share of Zhitong Hong Kong Stock Connect | January 1.
Statistics on abnormal changes in the proportion of the Stock Connect as of December 31, 2024.
On December 31, HAOHAI BIOTEC (06826) spent 0.71929 million Hong Kong dollars to repurchase 0.027 million shares listed in Hong Kong.
HAOHAI BIOTEC (06826) announced that on December 31, 2024, it spent 0.71929 million Hong Kong dollars to repurchase 2...
HAOHAI BIOTEC (06826.HK) has completed the cancellation of 0.9966 million H-shares.
Gelonghui, December 30th丨HAOHAI BIOTEC (06826.HK) announced that as of December 30, 2024, the company has completed the cancellation of 996,600 H shares repurchased. After the cancellation, the total share capital of the company changed from 234,190,295 shares to 233,193,695 shares.
HAOHAI BIOTEC (06826.HK) spent 0.2944 million yuan to repurchase 0.011 million shares on December 30.
Gelonghui, December 30丨HAOHAI BIOTEC (06826.HK) announced that on December 30, 2024, it spent 0.2944 million Hong Kong dollars to repurchase 0.011 million A-shares, with a repurchase price of 26.6-26.8 Hong Kong dollars per share. On the same day, the company spent 2.6256 million yuan to repurchase 0.043 million shares on the Shanghai Stock Exchange.
HAOHAI BIOTEC (06826.HK) spent 1.948 million yuan to repurchase 0.0315 million A shares on December 27.
Gelonghui, December 27th丨HAOHAI BIOTEC (06826.HK) announced that on December 27, 2024, it spent 1.948 million yuan to repurchase 0.0315 million A-shares at a repurchase price of 61.62-62 yuan per share.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
HAOHAI BIOTEC (06826.HK) spent 0.2913 million HKD to repurchase 0.011 million shares on December 23.
Gelonghui reported on December 23 that HAOHAI BIOTEC (06826.HK) announced that on December 23, 2024, it spent 0.2913 million Hong Kong dollars to repurchase 0.011 million shares, with a repurchase price of 26.45-26.5 Hong Kong dollars per share.
Recent 6.3% Pullback Would Hurt Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Insiders
HAOHAI BIOTEC (06826.HK) spent 1.0705 million HKD to repurchase 0.04 million shares on December 20.
Gelonghui reported on December 20 that HAOHAI BIOTEC (06826.HK) announced it spent HKD 1.0705 million to repurchase 0.04 million shares, with a repurchase price of HKD 26.7-26.85 per share. On the same day, the company spent RMB 1.9862 million to repurchase 0.032 million shares, with a repurchase price of RMB 61.94-62.2 per share.
HAOHAI BIOTEC (06826.HK) spent 1.048 million Hong Kong dollars to repurchase 0.039 million shares on December 19.
Gelonghui reported on December 19 that HAOHAI BIOTEC (06826.HK) announced that on December 19, it spent 1.048 million Hong Kong dollars to repurchase 0.039 million shares, with a repurchase price of 26.75-27 Hong Kong dollars per share.
HAOHAI BIOTEC (06826.HK) spent 0.282 million Hong Kong dollars to repurchase 0.0104 million shares on December 18.
On December 18, Gelonghui reported that HAOHAI BIOTEC (06826.HK) announced that on December 18, it spent 0.282 million Hong Kong dollars to repurchase 0.0104 million shares.
HAOHAI BIOTEC (06826.HK) spent 0.766 million HKD to repurchase 0.028 million shares on December 17.
Gelonghui, December 17: HAOHAI BIOTEC (06826.HK) announced that it spent 0.766 million Hong Kong dollars on December 17 to repurchase 0.028 million shares.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
On December 5, haohai biotec (06826) spent 0.8066 million Hong Kong dollars to repurchase 0.0295 million shares.
haohai biotec (06826) announced that the company invested 0.8066 million Hong Kong dollars on December 5, 2024...
Haohai Biotec (06826.HK) spent 0.199 million HKD to repurchase 7,200 shares on December 4.
On December 4, haohai biotec (06826.HK) announced that it spent 0.199 million Hong Kong dollars to repurchase 7200 shares on December 4.
haohai biotec (06826.HK) spent 0.363 million Hong Kong dollars to repurchase 0.013 million shares on December 3.
Grain Meeting December 3rd | haohai biotec (06826.HK) announced that on December 3, 2024, it spent 0.363 million Hong Kong dollars to repurchase 0.013 million shares at a repurchase price of HK$27.85-28 per share.
haohai biotec (06826.HK) has repurchased a total of 0.138 million shares of A-shares as of November 30, 2024.
Gelonghui, December 2nd丨haohai biotec (06826.HK) announced that as of November 30, 2024, the company has repurchased a total of 138,150 A-shares through centralized bidding trade, accounting for 0.06% of the company's total share capital of 234,190,295 shares. The highest fill price was 63.58 yuan per share, the lowest fill price was 62.73 yuan per share, and the total transaction amount was 8,725,748.33 yuan (excluding stamp duty, transaction commission, and other transaction costs).
No Data
